2 results match your criteria: "Amyloidosis Research and Treatment Center Foundation[Affiliation]"
Background: For the time being, tafamidis is the only approved treatment for wild-type transthyretin cardiac amyloidosis. However, benefits on all-cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age.
View Article and Find Full Text PDFAvoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.
BMC Fam Pract
September 2020
Amyloidosis Research and Treatment Center Foundation, IRCCS Policlinico San Matteo, San Matteo, Italy.
Article Synopsis
- Transthyretin amyloidosis (ATTR amyloidosis) is a serious disease where a protein builds up in organs, making it hard for them to work properly.
- Recognizing the early symptoms can be tricky, and many doctors need more info to diagnose it correctly, which can delay treatment.
- Recently, new treatments have been found, and experts are suggesting a clear way to identify patients who might have this disease based on specific warning signs.